iPSC Signature Series Event

iPSCs: From Bench to Bedside

Since induced pluripotent stem cells (iPSCs) were first developed, in 2006, they have represented an area of immense potential in disease modeling, drug discovery, and therapeutics. In recent years, advances in biology and technology have accelerated their entry into the clinical arena, and leading researchers globally are now progressing iPSC products across a wide range of indications. Despite these recent advances, significant manufacturing and regulatory hurdles stand between promising iPSC research and their entry into the market as viable solutions for patients.

The 2024 Signature Series Event ‘iPSCs: From Bench to Bedside’ will mirror product development, addressing key challenges and questions arising at each stage of the cycle. Global key opinion leaders from academic research labs and clinical centers, regulatory agencies, and industry, will gather in Vancouver to discuss and deliberate on pressing topics, including autologous versus allogeneic starting materials; CMC, translational hurdles and effective preclinical strategies; genomic stability; regulatory requirements and heterogeneity across jurisdictions; and ongoing clinical trial results.

Join us as we develop a roadmap for future regulatory approvals and clinical adoption of iPSC products.

PROGRAM TOPICS


SESSION I
Autologous vs Allogeneic Starting Materials
Chair: Bruno Marques, PhD, Century Therapeutics, United States


SESSION II
CMC: Developing Effective Strategies to Assess Function and Potency Throughout the iPSC-Derived Product Lifecycle
Chair: Joanne Mountford, PhD, Scottish National Blood Transfusion Service, United Kingdom


SESSION III
Deep Characterization for iPSC-derived Product Development: Genomic Stability Testing
Chair: Xiaokui Zhang, PhD, Aspen Neuroscience, United States


SESSION IV
Regulatory Requirements and Heterogeneity Across Jurisdictions
Chair: Wanxing Cui, MD, PhD, Georgetown University Hospital, United States


SESSION V
Ongoing Clinical Trials
Chair: Shin Kawamata, MD, PhD, Cyto-Facto, Japan


Closing Panel and Future Directions

Full speaker lineup to be announced

DATE

Saturday, June 1, 2024

AGENDA

  • Morning Sessions: 8:30-12:15
  • Lunch: 12:15-12:45
  • Afternoon Sessions: 12:45-16:00
  • Scientific Signature Series Cocktail Reception: 16:00-17:30

EVENT CO-CHAIRS

Joanne Mountford
PhD

Scottish National Blood Transfusion Service
United Kingdom

Shin Kawamata
MD, PhD

Cyto-Facto
Japan

REGISTRATION

Registration is exclusive to ISCT 2024 Full Conference Delegates only.

Registration for this event is possible as an add-on during registration for the full ISCT 2024 conference. Additional registration and fee of $35 USD + 5% GST is required to attend.

Limited seats available on a first-come first-serve basis. Register early to secure your spot.

Already registered for ISCT 2024? Please contact Vanessa Ho to add this event to your registration package (VanessaHo@isctglobal.org)

FULL PROGRAM COMING SOON